Skip to main content
OpenTrials
Completed

NCT Number: NCT03795025

ContraTRAIN - a Validation Study of Contralateral Training Protocols

This study aims to validate the use of contralateral designs in studies of effects of resistance exercise. It will recruit healthy young (18-35 years) individuals, which will be allocated to 4 experimental groups. In two of the experimental groups, 3x10 or 6x10 repetitions of heavy resistance exercise on one leg will be combined with no training of the other leg for 7 weeks. In the third group, 3x10 repetitions of heavy resistance exercise on one leg will be combined with 6x10 repetitions of heavy resistance exercise on the other leg for 7 weeks. In the fourth group, which serves as a control group, a period of no training (similar in length to the training period of groups 1-3; 7 weeks), before both legs will train 3x10 repetitions of heavy resistance exercise in an unilateral manner.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Inland Norway University of Applied Sciences

Lillehammer, Norway

About this study

Our understanding of how exercise affects muscular adaptations at the cellular and molecular level comes from the use of skeletal muscle biopsies. Such studies are met by several challenges, including its invasive nature, costs of muscle analyses, large inter-participant variability in response to exercise and a limited number of subjects (related to ethical concerns regarding exposing participants to biopsies). Consequently, studies often include small sample sizes, resulting in low statistical power. This poses a great challenge to the field of exercise physiology. While increasing sample size may not always be feasible, employing alternative designs may offer a way to increase the statistical power. An example of such a design is the so-called cross-over design, wherein participants serve as their own control thereby reducing the inter-participant variation. An interesting variant of the cross-over design is the unilateral or contralateral exercise model. In such designs, each of the participant's limbs (e.g. legs) are randomly allocated to perform different types of training/treatments in close temporal proximity. This design obliterates the need for a wash-out period and removes the potential effects of confounding factors such as diet, activity and sleep decreases. Thus, resources, time spent and variability can be reduced. However, validation of such studies is lacking.

In an effort to validate a contralateral training design, the investigators will recruit young (18-35 years) healthy individuals to 4 groups performing unilateral progressive strength training; (1) one leg with no training and one leg with 3x10 maximal repetitions, (2) one leg with no training and one leg with 6x10 maximal repetitions, (3) one leg with 3x10 maximal repetitions and one leg with 6x10 maximal repetitions and (4) a control group with an initial period of no training (similar in length to the training period of groups 1-3) followed by a period of 3x10 maximal repetitions on each leg. Leg training will consist of one-legged leg press and one-legged knee extensions. All groups, except the control group (during the no-training control period), will train the upper body by 3x10 maximal repetitions in bench press and lying rowing. Prior to the 7 week training intervention, all four groups will go through a 3-week period of familiarization to training and repeated testing (4 test time points for performance measures).

This design allows us to investigate the benefits of a contralateral design compared to the more common two-group design, the intra-individual variation vs the inter-individual variation, the potential contralateral effect of training one leg on the physiology and functional abilities of the non-trained leg, and whether or not these perspective are affected by training volume. We will also investigate whether participant classification into low or high responders is universal across several measures of muscle mass and strength, and between different training volumes. Further, by measuring several hypertrophy-related outcomes (e.g. changes in ribosome volume, activation of satellite cells and transcriptional changes), the investigators will extend previous findings regarding the effects of training volume on these variables and their ability to predict training outcomes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy

Exclusion criteria

  • Smoking
  • Strength training more than 2 times per months for the last 6 months
  • Endurance training more than 3 hours per week
  • Adverse reactions to lidocaine
  • Consumption of supplements or medication affecting muscular adaptations to strength training

Treatment and study plan

Strength training 3x10RM + no training

Other

Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.

Strength training 6x10RM + no training

Other

Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.

3x10RM + 6x10RM

Other

Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.

Primary outcomes

  1. Muscle fiber area

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Muscle cell cross-sectional area measured in biopsies from m. vastus lateralis using immunohistochemistry

Secondary outcomes

  1. Body mass composition

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Body mass composition measured using Dual-energy X-ray absorptiometry (DXA)

  2. Rate of muscle protein synthesis (%/day)

    Time frame: Mesured over 3 days in week 7 of the study

    By ingesting deuterium we will label alanine to measure the rate of its incorporation into muscle proteins. This is done by collection of blood before, during and after, and a biopsy 3 days after deuterium ingestion to be analyzed with chromatography and mass spectrometry. Results will be reported as a rate of synthesis in %/day.

  3. M. vastus lateralis thickness

    Time frame: Changes over the course of the intervention (0-10 weeks)

    M. vastus lateralis thickness mesured by ultrasound

  4. Unilateral leg press strength (1RM test)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the lower body to exert maximal force during dynamic movements in a leg press

  5. Unilateral knee extension strength (1RM test)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the lower body to exert maximal force during dynamic movements in a knee extension

  6. Barbell bench press muscle strength (1RM test)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the upper body to exert maximal force during dynamic movements in a bench press

  7. Lying rowing muscle strength (1RM test)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the upper body to exert maximal force during dynamic movements in a lying row exercise

  8. Unilateral lower body isokinetic muscle strength at 60 and 240 deg per second in a mechanical dynamometer (Humac NORM)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the lower body to exert maximal force during isokinetic movements

  9. Unilateral lower body isometric muscle strength in a mechanical dynamometer (Humac NORM)

    Time frame: Changes over the course of the intervention (0-10 weeks)

    The ability of muscles of the lower body to exert maximal force during isometric contractions

  10. One-legged cycling

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Performance indicies measured during an incremental one-legged cycling test

  11. Muscle phenotype

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Muscle fiber type composition measured in biopsies from m. vastus lateralis using immunohistochemistry

  12. Muscle cell biological traits

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Muscle cell biological traits, including numbers of myonuclei, satelitte cells and capillaries, measured in biopsies from m. vastus lateralis using immunohistochemistry

  13. Gene expression in skeletal muscle

    Time frame: Changes over the course of the intervention (0-10 weeks)

    RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome

  14. Protein abundances in skeletal muscle measured by western blot

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome

  15. Hormones in blood

    Time frame: Changes over the course of the intervention (0-10 weeks)

    Levels of hormones in blood

Sponsors and collaborators

Lead sponsor

Inland Norway University of Applied Sciences

Other

Collaborators

  • University of Birmingham

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jan 7, 2019
Registry last updated
May 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.